好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Treatment-induced Changes in Cognitive-gait Interactions and Event-related EEG Potentials in Parkinson’s Disease
Movement Disorders
P3 - Poster Session 3 (11:45 AM-12:45 PM)
5-026
To measure the effects of levodopa and deep brain stimulation (DBS) on response inhibition, gait speed, and event-related EEG potentials (ERPs) in people with Parkinson’s disease (PwPD) during performance of a response inhibition task while walking.
ERPs can non-invasively measure neural processes associated with cognitive-gait interactions. When performing a response inhibition task while walking, the first ERP component (N1) reflects early sensory-perceptual processes. The second component (N2) reflects subsequent “go/no-go” conflict monitoring and response selection processes. The third component (P3) reflects response inhibition processes. ERPs could reveal distinct mechanisms underlying disease and treatment-induced changes in cognitive-gait interactions, which could lead to improved outcomes in PwPD (e.g. freezing of gait, falls).
We measured response accuracy, treadmill-walking speed, and ERPs in PwPD as they completed a “go/no-go” response inhibition task while walking on a treadmill during four distinct levodopa/DBS treatment conditions (-levodopa/-DBS, -levodopa/+DBS, +levodopa/-DBS, +levodopa/+DBS). We used paired t-tests to evaluate differences among the treatment conditions with respect to response accuracy, treadmill-walking speed, and the mean amplitudes of the ERP components.
Ten PwPD (58-79 years-old, 2 females) had lower response accuracy, slower treadmill-walking speed, higher N1 mean amplitude, and lower N2 and P3 mean amplitudes during the -levodopa/-DBS condition. Response accuracy improved only during the +levodopa/+DBS condition (p=0.03). Walking speed improved during the -levodopa/+DBS, +levodopa/-DBS and +levodopa/+DBS conditions. The mean N1 amplitude improved during the +levodopa/-DBS condition (p<0.05). The mean N2 and P3 amplitudes improved during the -levodopa/+DBS condition (p<0.05).

During a response inhibition task while walking, ERPs might reveal distinct mechanisms of treatment-induced changes in cognitive-gait interactions in PwPD. In these preliminary data, only the combination of levodopa and DBS was associated with improved response accuracy. Levodopa could improve the initial sensory-perceptual processes (N1) and DBS could improve subsequent cognitive processes associated with the task (N2 and P3).
Authors/Disclosures
Karlo J. Lizarraga, MD, MS, FAAN (University of Rochester)
PRESENTER 		Dr. Lizarraga has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for FHC. The institution of Dr. Lizarraga has received research support from BlueRock. The institution of Dr. Lizarraga has received research support from Roche. The institution of Dr. Lizarraga has received research support from NIH/NINDS. Dr. Lizarraga has received personal compensation in the range of $500-$4,999 for serving as a Speaker with International Parkinson and Movement Disorders Society. Dr. Lizarraga has received personal compensation in the range of $0-$499 for serving as a Reviewer with National Institutes of Health. Dr. Lizarraga has a non-compensated relationship as a Editorial Board Member for Brain & Life with 好色先生 that is relevant to AAN interests or activities.
Eleni Patelaki, PhD Dr. Patelaki has nothing to disclose.
Jeehyun Kim Ms. Kim has nothing to disclose.
Michael McDermott, PhD Dr. McDermott has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly & Company. Dr. McDermott has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurocrine Biosciences, Inc.. Dr. McDermott has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ReveraGen BioPharma, Inc.. Dr. McDermott has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NS Pharma, Inc.. Dr. McDermott has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Prilenia Therapeutics Development, Inc.. Dr. McDermott has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Seelos Therapeutics, Inc.. The institution of Dr. McDermott has received research support from NIH. The institution of Dr. McDermott has received research support from FDA. The institution of Dr. McDermott has received research support from Cure SMA.
Mark Hallett, MD, FAAN (National Institutes of Health) Dr. Hallett has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Hallett has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. Dr. Hallett has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Brainsway. Dr. Hallett has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for VoxNeuro. Dr. Hallett has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for QuantalX. Dr. Hallett has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Hallett has received intellectual property interests from a discovery or technology relating to health care. Dr. Hallett has received publishing royalties from a publication relating to health care. Dr. Hallett has received publishing royalties from a publication relating to health care. Dr. Hallett has received publishing royalties from a publication relating to health care. Dr. Hallett has received publishing royalties from a publication relating to health care. Dr. Hallett has received personal compensation in the range of $500-$4,999 for serving as a Speaker with International Parkinson and Movement Disorder Society. Dr. Hallett has a non-compensated relationship as a Past-President with Functional Neurological Disorder Society that is relevant to AAN interests or activities.
Michael S. Okun, MD, FAAN (University of Florida) Dr. Okun has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH. Dr. Okun has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Parkinson's Foundation. Dr. Okun has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Okun has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NEJM Journal Watch. The institution of Dr. Okun has received research support from NIH. The institution of Dr. Okun has received research support from Parkinson's Foundation. The institution of Dr. Okun has received research support from Tourette Association of America. The institution of Dr. Okun has received research support from Michael J Fox. Dr. Okun has received publishing royalties from a publication relating to health care.
Miriam T. Weber The institution of Miriam T. Weber has received research support from NIH.
ed freedman, PhD Prof. freedman has nothing to disclose.
John J. Foxe, PhD Prof. Foxe has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Federation of European Neuroscience Societies. The institution of Prof. Foxe has received research support from National Institutes of Heath.